{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:07:34Z","timestamp":1792786054506,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"3","funder":[{"name":"Collaborative Ependymoma Research Network and Glaxo Smith Kline"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>No standard medical treatment exists for adult patients with recurrent ependymoma, and prospective clinical trials in this population have not succeeded because of its rarity and challenges in accruing patients. The Collaborative Ependymoma Research Network conducted a prospective phase II clinical trial of dose-dense temozolomide (TMZ) and lapatinib, targeting the unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter status and increased expression of ErbB2 (human epidermal growth factor receptor 2) and ErbB1 (epidermal growth factor receptor) in ependymomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients age 18 or older with histologically proven and progressive ependymoma or anaplastic ependymoma were eligible and received dose-dense TMZ and daily lapatinib. The primary outcome measure was median progression-free survival (PFS). Landmark 6- and 12-month PFS and objective response were measured. Serial assessments of symptom burden using the MD Anderson Symptom Inventory Brain Tumor (MDASI-BT)\/MDASI\u2013Spine Tumor modules were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 50 patients enrolled had a median age of 43.5 years, median Karnofsky performance status of 90, and a median of 2 prior relapses. Twenty patients had grade III, 16 grade II, and 8 grade I ependymoma. Half had spinal cord tumors; 15 had a supratentorial tumor, 8 infratentorial, and 2 had disseminated disease. Treatment was well tolerated. The median PFS was 7.8 months (95% CI: 5.5,12.2); the 6- and 12-month PFS rates were 55% and 38%, with 2 complete and 6 partial responses. Measures of symptom burden showed reduction in moderate-severe pain and other disease-related symptoms in most patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This treatment, with demonstrated clinical activity with objective responses and prolonged disease control associated with disease-related symptom improvements, is an option as a salvage regimen for adult patients with recurrent ependymoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noaa240","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T15:13:17Z","timestamp":1602861197000},"page":"468-477","source":"Crossref","is-referenced-by-count":62,"title":["A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma"],"prefix":"10.1093","volume":"23","author":[{"given":"Mark R","family":"Gilbert","sequence":"first","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3163-480X","authenticated-orcid":false,"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Wu","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8122-5233","authenticated-orcid":false,"given":"Tito","family":"Mendoza","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas"},{"name":"Henry Ford Hospital, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Vera","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Omuro","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Lieberman","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H Ian","family":"Robins","sequence":"additional","affiliation":[{"name":"University of Wisconsin\u2013Madison, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R","family":"Gerstner","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y","family":"Wen","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Mikkelsen","sequence":"additional","affiliation":[{"name":"Henry Ford Hospital, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Aldape","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2414-0492","authenticated-orcid":false,"given":"Terri S","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"issue":"1","key":"2021032513201888800_CIT0001","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11060-019-03215-x","article-title":"Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT","volume":"144","author":"Truitt","year":"2019","journal-title":"J Neurooncol."},{"issue":"6","key":"2021032513201888800_CIT0002","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2021032513201888800_CIT0003","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/neuonc\/nou162","article-title":"Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients","volume":"17","author":"Vera-Bolanos","year":"2015","journal-title":"Neuro Oncol."},{"issue":"5","key":"2021032513201888800_CIT0004","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bpa.12866","article-title":"cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors","volume":"30","author":"Ellison","year":"2020","journal-title":"Brain Pathol."},{"issue":"5","key":"2021032513201888800_CIT0005","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","article-title":"Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups","volume":"27","author":"Pajtler","year":"2015","journal-title":"Cancer Cell."},{"issue":"6","key":"2021032513201888800_CIT0006","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00401-019-02056-2","article-title":"MYCN amplification drives an aggressive form of spinal ependymoma","volume":"138","author":"Ghasemi","year":"2019","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2021032513201888800_CIT0007","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40478-020-00973-y","article-title":"High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma","volume":"8","author":"Raffeld","year":"2020","journal-title":"Acta Neuropathol Commun."},{"key":"2021032513201888800_CIT0008","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/neuonc\/nox166","article-title":"EANO guidelines for the diagnosis and treatment of ependymal tumors","volume":"20","author":"Ruda","year":"2018","journal-title":"Neuro Oncol."},{"issue":"4","key":"2021032513201888800_CIT0009","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3171\/jns.2005.102.4.0629","article-title":"Is gross-total resection sufficient treatment for posterior fossa ependymomas?","volume":"102","author":"Rogers","year":"2005","journal-title":"J Neurosurg."},{"issue":"1","key":"2021032513201888800_CIT0010","first-page":"71","article-title":"Adjuvant treatments for ependymomas","volume":"62","author":"Sartor","year":"2018","journal-title":"J Neurosurg Sci."},{"issue":"2","key":"2021032513201888800_CIT0011","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ijrobp.2017.10.002","article-title":"Outcomes after reirradiation for recurrent pediatric intracranial ependymoma","volume":"100","author":"Tsang","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2021032513201888800_CIT0012","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/cncr.21110","article-title":"A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia","volume":"104","author":"Brandes","year":"2005","journal-title":"Cancer."},{"issue":"1","key":"2021032513201888800_CIT0013","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.coc.0000158891.09531.11","article-title":"A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy","volume":"29","author":"Rehman","year":"2006","journal-title":"Am J Clin Oncol."},{"issue":"2","key":"2021032513201888800_CIT0014","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/neuonc\/nov167","article-title":"Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study","volume":"18","author":"Rud\u00e0","year":"2016","journal-title":"Neuro Oncol."},{"issue":"1","key":"2021032513201888800_CIT0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1215\/15228517-2008-078","article-title":"New (alternative) temozolomide regimens for the treatment of glioma","volume":"11","author":"Wick","year":"2009","journal-title":"Neuro Oncol."},{"issue":"32","key":"2021032513201888800_CIT0016","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol."},{"issue":"7","key":"2021032513201888800_CIT0017","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.bjc.6600827","article-title":"Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules","volume":"88","author":"Tolcher","year":"2003","journal-title":"Br J Cancer."},{"issue":"2","key":"2021032513201888800_CIT0018","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1179\/joc.2008.20.2.263","article-title":"O6-methylguanine-DNA-methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry","volume":"20","author":"Buccoliero","year":"2008","journal-title":"J Chemother."},{"issue":"10","key":"2021032513201888800_CIT0019","first-page":"3054","article-title":"ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease","volume":"8","author":"Gilbertson","year":"2002","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2021032513201888800_CIT0020","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00381-015-2981-2","article-title":"Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma","volume":"32","author":"Friedrich","year":"2016","journal-title":"Childs Nerv Syst."},{"issue":"41","key":"2021032513201888800_CIT0021","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","article-title":"Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR\/erbB2 and downstream Erk1\/2 and AKT pathways","volume":"21","author":"Xia","year":"2002","journal-title":"Oncogene."},{"issue":"1","key":"2021032513201888800_CIT0022","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11060-006-9135-z","article-title":"Validation of the M.D. Anderson symptom inventory brain tumor module (MDASI-BT)","volume":"80","author":"Armstrong","year":"2006","journal-title":"J Neurooncol."},{"issue":"4","key":"2021032513201888800_CIT0023","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3171\/2009.10.SPINE0943","article-title":"Reliability and validity of the M. D. Anderson symptom inventory-spine tumor module","volume":"12","author":"Armstrong","year":"2010","journal-title":"J Neurosurg Spine."},{"issue":"7","key":"2021032513201888800_CIT0024","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaa240\/35514923\/noaa240.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/3\/468\/36722863\/noaa240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/3\/468\/36722863\/noaa240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:45:43Z","timestamp":1696877143000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/23\/3\/468\/5934559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,10,21]]},"published-print":{"date-parts":[[2021,3,25]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaa240","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,10,21]]}}}